George Louis Drusano MD

PubMed

• 15 citations
  First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus
  Alaa R. M. Sayed, Nirav Shah, Kari B. Basso, Manasi Kamat, Yuanyuan Jiao
  Antimicrobial Agents and Chemotherapy. 2020-12-16
• 2 citations
  Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
  George L. Drusano, Brandon Duncanson, Charles A. Scanga, Sarah Kim, Stephan Schmidt
  Antimicrobial Agents and Chemotherapy. 2020-11-17
• 10 citations
  Building Optimal Three-Drug Combination Chemotherapy Regimens.
  George L. Drusano, Michael Neely, Sarah Kim, Walter M. Yamada, Stephan Schmidt
  Antimicrobial Agents and Chemotherapy. 2020-10-20

Journal Articles

• Meropenem plus Levofloxacin is Synergistic for the Therapy of Pseudomonas aeruginosa as Tested in a Murine Model of Pneumonia  
  Louie A, W Liu, M VanGuilder, MN Neely, A Schumitzky, R Jelliffe, S Fikes, S Kurhanewicz, N Robbins, D Brown, Dodge Baluya, GL Drusano, J Infect Dis, 1/1/2015
• Pharmacokinetic Determinants of Virological Response to Raltegravir in the In Vitro Pharmacodynamic Hollow-Fiber Infection Model System  
  Brown AN, JR Adams, DL Baluya, GL Drusano, Antimicrob Agents Chemother, 1/1/2015
• In Memoriam: William A Craig  
  Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sorgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL, Antimicrob Agents Chemother, 1/1/2015
• Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance  
  Docobo-Perez F, GL Drusano, A Johnson, J Goodwin, S Whalley, V Ramos-Martín, M Ballestero-Tellez, JM Rodriguez-Martinez, C Conejo, M van Guilder, J Rodríguez-Baño1,, A..., Antimicrob Agents Chemother, 1/1/2015
• Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with ...  
  Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA, J Antimicrob Chemother, 1/19/2014
• Are vancomycin troughs adequate for optimal dosing?  
  Neely M, G Youn, B Jones, R Jelliffe, G Drusano, K Rodvold, T Lodise, Antimicrob Agents Chemother, 1/1/2014
• Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults  
  Hendricks KA, ME Wright, SV Shadomy, et al and the Workgroup on Anthrax Clinical Guidelines, Emerg Infect Dis, 1/1/2014
• Evaluation of Imipenem for the Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague  
  Heine H, A Louie, J Adamovicz, K Amemiya, R Fast, L Miller, S Opal, J Palardy, N Parejo, F Sörgel, M Kinzig-Schippers, GL Drusano, Antimicrob Agents Chemother, 1/1/2014
• Vancomycin Exposure in Patients with MRSA Bloodstream Infections: How much is enough?  
  T.P. Lodise; G.L. Drusano; E. Zasowski; A. Dihmess; V. Lazariu; L. Cosler; L.A. McNutt, Clinical Infectious Diseases, 1/1/2014
• Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model  
  Drusano GL, W Liu, S Fikes, R Cirz, N Robbins, S Kurhanewicz, J Rodriquez, D Brown, D Baluya, A Louie, J Infect Dis, 1/1/2014
• Use of pharmacokinetics/pharmacodynamics systems analyses to inform dose selection for tedizolid phosphate  
  Lodise TP and GL Drusano, Clin Infect Dis, 1/1/2014
• Editorial commentary: saving lives with optimal antimicrobial chemotherapy  
  Drusano GL, TP Lodise, Clin Infect Dis, 1/1/2013
• Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia  
  Louie A, W Liu, S Fikes, D Brown, GL Drusano, Antimicrob Agents Chemother, 1/1/2013
• Early endpoints for ABSSSI  
  Drusano GL, Antimicrob Agents Chemother, 1/6/2012
• Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa  
  Drusano GL, RA Bonomo, N Bahniuk, JB Bulitta, B van Scoy, H Defiglio, S Fikes, D Brown, SM Drawz, R Kulawy, A Louie, Antimicrob Agents Chemother, 1/1/2012
• Dosing Regimen Matters: The Importance of Early Intervention and Rapid Attainment of the PK/PD Target  
  Martinez M, M Papich, GL Drusano, Antimicrob Agents Chemother, 1/1/2012
• New EMA guideline for antimicrobial development  
  Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL, Lancet Infect Dis, 1/1/2012
• Effect of Co-administration of Moxifloxacin and Rifampin on Mycobacterium tuberculosis in a Murine Aerosol Infection Model  
  V. Balasubramanian, S Solapure, S Gaonkar, KN Mahesh Kumar, RK Shandil, Abhijeet Deshpande, N. Kumar, KG Vishwas, V. Panduga, J. Reddy, S. Ganguly, A. Louie, G. Drusano, Antimicrob Agents Chemother, 1/1/2012
• Population pharmacokinetics of extended infusion Piperacillin/Tazobactam in hospitalized patients with nosocomial infections  
  Felton T, W Hope, B Lomaestro, J Butterfield, A Kwa, G Drusano, T Lodise, Antimicrob Agents Chemother, 1/1/2012
• Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile  
  Landersdorfer CB, JB Bulitta, CMJ Kirkpatrick, M Kinzig, U Holzgrabe, GL Drusano, U Stephan, F Sorgel, Antimicrob Agents Chemother, 1/1/2012
• Effect of administering moxifloxacin plus rifampin against Mycobacterium tuberculosis 7 of 7 Days versus 5 of 7 Days in an in Vitro pharmacodynamic system  
  Drusano GL, N Sgambati, A Eichas, D Brown, R Kulawy, A Louie, mBio, 1/12/2011
• Use of an In Vitro Pharmacodynamic Model to Derive a Moxifloxacin Regimen that Optimizes Kill of Yersinia pestis and Prevents Emergence of Resistance  
  215. Louie A, HS Heine, B Vanscoy, A Eichas, K Files, S Fikes, DL Brown, W Liu, M Kinzig-Schippers, F Sorgel, GL Drusano, Antimicrob Agents Chemother, 1/1/2011
• Pharmacokinetics and pharmacodynamics: Optimal antimicrobial therapy in the intensive care unit  
  Lodise T and GL Drusano, Crit Care Clin, 1/1/2011
• The Effect of Half-Life on the Pharmacodynamic Index of Zanamivir Against Influenza Virus as Delineated by a Mathematical Model  
  Brown AN, JB Bulitta, JJ McSharry, Q Weng, JR Adams, R Kulawy, GL Drusano, Antimicrob Agents Chemother, 1/1/2011
• Zanamivir, at 600 mg Twice Daily, Inhibits Oseltamivir–Resistant 2009 pandemic H1N1 Influenza Virus in an in vitro Hollow Fiber Infection Model System  
  Brown AN, JJ McSharry, Q Weng, JR Adams, R Kulawy, GL Drusano, Antimicrob Agents Chemother, 1/1/2011
• Join now to see all

Books/Book Chapters

• Applied Pharmacometrics, AAPS Advances in the Pharmaceutical Sciences Series 
  Chapter: Pharmacometrics in Viral Infections 
  Drusano, G.L. and A.N. BrownEditors: Schmidt, S. and Derendorf, H..Springer, New York, NY2014
• Antimicrobial Pharmacodynamics in Theory and Clinical Practice 
  Editors: Nightengale CH, Ambrose PG, Drusano GL, Murakawa T.Informa Healthcare, New York, NY; London, UKEdition 2nd,2007
• Mycobacterium avium-Complex Infection. Progress in Research and Treatment 
  Chapter: Pharmacokinetics of Drugs Used for the Therapy of Mycobacterium avium-Complex Infection 
  Killian AD, Kanyok TP, Drusano GLMarcel Dekker, Inc, New York, NY1996
• Principles and Practice of Infectious Diseases 
  Chapter: Pharmacology of Anti-Infective Agents 
  Drusano G.L.Editors: Mandel G., Douglas R.G. and Bennett J.E..Churchill Livingstone, New York, NY1994
• Emerging Targets in Antibacterial and Antifungal Chemotherapy 
  Chapter: Bacterial Pathogens for the 90's: A Case for New Drug Development 
  Page 24 - 36Drusano, G.L.Editors: Georgopapadakou, N. & Sutcliffe, J.Routledge, Hall and Chapman, New York, NY1992
• Quinolone Antimicrobial Agents 
  Chapter: Pharmacokinetics of the Quinolone Antimicrobial Agents 
  Page 71 - 105Drusano, G.L.Editors: Wolfson, J.S., Hooper, D.C..American Society for Microbiology, Washington, D.C.1989
• Emergency Diagnosis and Management of Infectious Diseases in Principles and Practice of Emergency Medicine 
  W.B. Saunders Co., Philadelphia, PA, London, UK; Toronto, CanadaEdition 2nd,1984
• The High Risk Patient: Management of the Critically Ill 
  Chapter: Critical Care Antimicrobials: Choose and Use 
  West B.C. and G.L. DrusanoEditors: Sivak, E.D..
• Antimicrobial Pharmacodynamics in Theory and in Clinical Practice 
  Chapter: Human Pharmacodynamics of Anti-Infectives: Determination from Clinical Trial Data 
  Drusano GLEditors: Nightingale, Murakawa and Ambrose.Marcel Dekker and Co
• Antimicrobial Pharmacodynamics in Theory and in Clinical Practice 
  Chapter: Pharmacodynamics of Antivirals 
  Page 259 - 284Drusano GL, SL Preston and PJ PilieroEditors: Nightingale, Murakawa and Ambrose.Marcel Dekker and Co
• Antimicrobial Pharmacodynamics in Theory and in Clinical Practice 
  Chapter: Pharmacodynamics of Antivirals.Chapter 
  Page 295 - 314Drusano GLEditors: Nightingale, Ambrose, Drusano and Murakawa.Informa HealthcareEdition 2nd,
• Antimicrobial Pharmacodynamics in Theory and in Clinical Practic 
  Chapter: Modeling of Toxicities Due to Antibiotics 
  Page 449 - 462Forrest A and Drusano GLEditors: Nightingale, Ambrose, Drusano and Murakawa.
• Goldman’s Cecil Medicine 
  Chapter: Antibacterial Chemotherapy 
  Page 1803 - 1814Drusano GL and Craig WAEditors: Goldman and Schafer.Elsevier Saunders, Philadelphia, PAEdition 24th,
• Join now to see all